Latest

Lecanemab

·February 17, 2026·6 min read

Brain Swelling Reveals Alzheimer’s Treatment Success

It’s the side effect every Alzheimer’s patient fears, but it might actually be a sign of success. New research shows brain swelling is tied to better plaque clearance.

Featured Neurology Neuroscience

·November 12, 2025·5 min read

Alzheimer’s Drug Reduces Amyloid but Fails to Restore Brain Waste Flow

Researchers found that lecanemab, the Alzheimer’s drug designed to clear amyloid-β plaques, does not improve the brain’s waste clearance system in the short term. In a three-month study using MRI-based DTI-ALPS imaging, scientists observed no measurable recovery in glymphatic function after treatment.

Featured Neurology Neuroscience

·November 30, 2022·4 min read

Alzheimer’s Amyloid-Clearing Monoclonal Antibody Drug Lecanemab Shows Positive Results, Poised for FDA Approval

Lecanemab, an amyloid-clearing monoclonal antibody drug shows positive results in the treatment of Alzheimer's disease. The drug is now poised for FDA approval early in 2023. Lecanemab slows cognitive decline by 27%.